Ablation Index in Standard vs. High Power Radiofrequency Ablation for Typical Atrial Flutter: A Randomized Study (AITAF) - Trial NCT06406686
Access comprehensive clinical trial information for NCT06406686 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Calgary and is currently Not yet recruiting. The study focuses on Atrial Flutter,Atrial Flutter Typical,Cavotricuspid Isthmus Dependent Macroreentry Tachycardia. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter
Interventional
procedure
Sponsor & Location
University of Calgary
Timeline & Enrollment
N/A
Jun 03, 2024
Jun 03, 2025
Primary Outcome
RF time to durable CTI block
Summary
A randomized controlled trial will be conducted to evaluate the efficacy of Ablation
 Index-guided high power - short duration (HPSD) ablation compared to conventional power
 settings in Cavotricuspid Isthmus (CTI) dependent atrial flutter. Participants will be
 randomized to receive either AI-guided HPSD ablation at 50 Watts or conventional power
 settings at 30 Watts. Both arms will use the Carto 3D mapping system and the QDOT MICRO
 ablation catheter (Biosense Webster). An anatomically contiguous line will be created with
 6mm inter-lesion distance. After a standardized wait time of 30 minutes, ablation success
 will be assessed. The primary outcome is total radiofrequency ablation time. Secondary
 outcomes include procedural time, fluoroscopy time, safety outcomes, and 3-month freedom from
 recurrence. It is our expectation that HPSD will result in a shorter primary outcome.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06406686
Non-Device Trial